Clinical Program Advances Following Favorable Safety Review; Peer-Reviewed Publication Further Validates Deciparticle™ Platform ...
In a paper published in Proceedings of the National Academy of Sciences, researchers from Technion and Tel Aviv University ...
More than a decade after Alice Corp. v. CLS Bank Int’l, the two-step framework for patent eligibility under 35 U.S.C. § 101 remains as contentious ...
Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...
A later generation of ATS cases involved multinational corporations accused of aiding and abetting state human rights ...
Mood and anxiety disorders represent a leading cause of disability worldwide. Current first-line pharmacological treatments, ...
The U.S. Lipid Nanoparticle CDMO Market is projected to reach USD 0.44 billion by 2035, while Europe is expected to reach USD 0.27 billion, driven by expanding mRNA, siRNA, gene-editing therapeutics, ...
VANCOUVER, BC / ACCESS Newswire / June 30, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news ...
Proven bacterial, viral, conjugate, and E.coli expression platforms support partners from discovery and process development to GMP readiness and clinical manufacturing ...
Flu season is no longer just flu season. Since 2022, the health care community has faced what's known as a "tripledemic" of ...
Publication Highlights Novel Intravenous Everolimus Formulation and Demonstrates Broad Potential of Deciparticle™ Technology for Hydrophobic ...
VANCOUVER, BC / ACCESS Newswire / June 23, 2026 / Onco-Innovations Limited (NEO:ONCO) ("Onco" or the "Company") is pleased to announce that it has entered into a services agreement with Nanosoft ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results